Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

In the first quarter of 2024, Dupixent generated global product sales of $3.09 billion (€2.84 billion), which were recorded by Sanofi, representing growth of 24.9% at a constant exchange rate.

Dupixent is a key top-line driver for Sanofi and Regeneron. During first-half 2024, Sanofi recorded €6.14 billion from Dupixent product sales, indicating 27% year-over-year growth.